

NHS Greater Glasgow and Clyde: New Medicines Decisions

In Scotland, a newly licensed medicine is routinely available in a health board only after it has been:

- accepted for use in NHSScotland by the Scottish Medicines Consortium (SMC), and
- accepted for use by the health board's Area Drug and Therapeutics Committee (ADTC).

All medicines accepted by SMC are available in Scotland, but may not be considered 'routinely available' within NHS Greater Glasgow and Clyde (NHSGG&C) because of available services and preferences.

'Routinely available' means that a medicine can be prescribed by the appropriately qualified person within a health board.

Each health board has an ADTC. The Greater Glasgow and Clyde ADTC is responsible for advising the NHSGG&C health board on all aspects of the use of medicines.

Medicines routinely available within NHSGG&C are usually included in the GGC Formulary. The Formulary is a list of medicines for use in the health board that has been agreed by ADTC in consultation with healthcare professionals to prescribe for common medical conditions. The GGC Formulary can help improve safety as prescribers are likely to become more familiar with the medicines included. Medicines included are consistent across the health board.

How does NHSGG&C decide which new medicines to make routinely available for patients?

The ADTC in NHSGG&C will consider national and local guidance before deciding whether to make a new medicine routinely available.

What national guidance does the ADTC consider?

- SMC advice: The SMC considers newly licensed medicines and advises health boards in Scotland whether they should be available. When SMC considers a new medicine for the NHS in Scotland
 - how well the medicine works,
 - which patients might benefit from it,
 - whether it is as good or better than medicines the NHS already uses to treat the medical condition, and
 - whether it is good value for money.
- In the table below, national guidance usually refers to SMC advice. Links to SMC advice for individual medicines are also included in the table.
- In some cases, other agencies may also provide guidance on how medicines should be used. For example, Healthcare Improvement Scotland issues alerts to advise if National Institute for Health and Care Excellence (NICE) Appraisals (NICE MTAs) are applicable in Scotland.

What local guidance does the ADTC consider?

- Advice from local clinical experts who would be expected to prescribe a particular medicine, where that service is available in NHSGG&C.

Why is a particular medicine not routinely available in NHSGG&C?

- This is usually because the medicine is not recommended for use in NHSScotland by the SMC.
- The medicine may not be routinely available in a health board, particularly in smaller health boards, because there is not a suitable specialist who may use the medicine.
- There may also be differences in which medicines are preferred in health boards. Sometimes SMC accepts more than one medicine for treating a specific medical condition. Clinical experts in each health board advise the ADTC on their preferred medicines to their formulary and advise the ADTC. Sometimes it is agreed that established medicines are a better choice than new medicines.

Medicine	Condition being treated	NHSGGC Decision	Date of decision
----------	-------------------------	-----------------	------------------

acalabrutinib	In combination with venetoclax with or without obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 08/06/2026	20/04/2026
Calquence®			
SMC2893			
axicabtagene ciloleucel	Treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 17/08/2026	20/04/2026
Yescarta®			
SMC2695			
baloxavir marboxil	Post-exposure prophylaxis of influenza in individuals aged 3 weeks and above.	Not routinely available as not recommended for use in NHSScotland	20/04/2026
Xofluza®			
SMC2921			
baloxavir marboxil	Treatment of uncomplicated influenza in patients aged 3 weeks and above.	Not routinely available as not recommended for use in NHSScotland	20/04/2026
Xofluza®			
SMC2920			
belantamab mafodotin	in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 17/08/2026	20/04/2026
Blenrep			
SMC2727			

Medicine	Condition being treated	NHSGGC Decision	Date of decision
budesonide Budenofalk® SMC2855	Short-term treatment of mild to moderate acute ulcerative colitis limited to the rectum (ulcerative proctitis) in adult patients.	Routinely available in line with national guidance	20/04/2026
cabozantinib SMC2754	Monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 17/08/2026	20/04/2026
ciclosporin Vevizye® SMC2873	Treatment of moderate to severe dry eye disease (keratoconjunctivitis sicca) in adult patients, which has not improved despite treatment with tear substitutes.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 08/06/2026	20/04/2026
delgocitinib Anzupgo® SMC2817	Treatment of moderate to severe chronic hand eczema (CHE) in adults for whom topical corticosteroids are inadequate or inappropriate.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 08/06/2026	20/04/2026

Medicine	Condition being treated	NHSGGC Decision	Date of decision
dostarlimab Jemperi® SMC2828	In combination with platinum-containing chemotherapy for the treatment of adult patients with primary advanced or recurrent endometrial cancer and who are candidates for systemic therapy.	Not routinely available as not recommended for use in NHSScotland	20/04/2026
durvalumab Imfinzi® SMC2857	In combination with tremelimumab for the first-line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC).	Routinely available in line with local or regional guidance	20/04/2026
eplontersen Wainzua® SMC2755	Treatment of hereditary transthyretin-mediated amyloidosis (ATTRv amyloidosis) in adult patients with Stage 1 and 2 polyneuropathy.	Routinely available in line with national guidance	20/04/2026
eszopiclone Lunivia® SMC2922	Treatment of insomnia, in adults, usually for short-term duration.	Not routinely available as not recommended for use in NHSScotland	20/04/2026

Medicine	Condition being treated	NHSGGC Decision	Date of decision
exagamglogene autotemcel Casgevy® SMC2852	Treatment of sickle cell disease in patients 12 years of age and older with recurrent vaso-occlusive crises who have the β S/ β S, β S/ β + or β S/ β 0 genotype, for whom haematopoietic stem cell transplantation is appropriate and a human leukocyte antigen matched related haematopoietic stem cell donor is not available.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 08/06/2026	20/04/2026
givinostat Duvyzat® SMC2856	Treatment of Duchenne muscular dystrophy (DMD) in patients 6 years of age and older.	Routinely available in line with national guidance	20/04/2026
guselkumab Tremfya® SMC2850	Treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic treatment.	Routinely available in line with national guidance	20/04/2026
guselkumab Tremfya® SMC2848	Treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy, a biologic treatment, or a Janus kinase (JAK) inhibitor.	Routinely available in line with national guidance	20/04/2026

Medicine	Condition being treated	NHSGGC Decision	Date of decision
isatuximab Sarclisa® SMC2914	In combination with bortezomib, lenalidomide, and dexamethasone, for the induction treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.	Not routinely available as not recommended for use in NHSScotland	20/04/2026
isatuximab Sarclisa® SMC2804	In combination with bortezomib, lenalidomide, and dexamethasone, for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 17/08/2026	20/04/2026
maralixibat Livmarli® SMC2806	Treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) 2 months of age and older.	Routinely available in line with national guidance	20/04/2026
marstacimab Hympavzi® SMC2759	for routine prophylaxis of bleeding episodes in patients 12 years of age and older, weighing at least 35 kg, with: <ul style="list-style-type: none"> •severe haemophilia A (congenital factor VIII deficiency, FVIII < 1%) without factor VIII inhibitors, or •severe haemophilia B (congenital factor IX deficiency, FIX < 1%) without factor IX inhibitors. 	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 08/06/2026	20/04/2026

Medicine	Condition being treated	NHSGGC Decision	Date of decision
nemolizumab Nemlurio® SMC2833	Treatment of moderate-to-severe atopic dermatitis in combination with topical corticosteroids and/or calcineurin inhibitors in adults and adolescents 12 years and older with a body weight of at least 30 kg, who are candidates for systemic therapy.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 08/06/2026	20/04/2026
nivolumab, ipilimumab NCMAG126	Neoadjuvant treatment of adults with mismatch repair deficient or microsatellite instability-high locally advanced colon cancer classified as T4 or borderline resectable	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 08/06/2026	20/04/2026
omaveloxolone Skyclarys® SMC2845	Treatment of Friedreich's ataxia in adults and adolescents aged 16 years and older.	Not routinely available as not recommended for use in NHSScotland	20/04/2026
osimertinib Tagrisso® SMC2815	Treatment of adult patients with locally advanced, unresectable (stage III) non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations and whose disease has not progressed during or following platinum-based chemoradiation therapy.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 08/06/2026	20/04/2026

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<p>pembrolizumab</p> <p>Keytruda®</p> <p>SMC2915</p>	<p>In combination with pemetrexed and platinum chemotherapy for the first-line treatment of adults with unresectable non-epithelioid malignant pleural mesothelioma.</p>	<p>Not routinely available as not recommended for use in NHSScotland</p>	<p>20/04/2026</p>
<p>pembrolizumab</p> <p>Keytruda®</p> <p>SMC2829</p>	<p>In combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), for the treatment of FIGO 2014 Stage III - IVA locally advanced cervical cancer in adults who have not received prior definitive therapy.</p>	<p>Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 08/06/2026</p>	<p>20/04/2026</p>
<p>progesterone</p> <p>Prometrium®</p> <p>SMC2869</p>	<p>Prevention of miscarriage in women presenting with bleeding in the first trimester of pregnancy and have a history of recurrent miscarriages</p>	<p>Routinely available in line with national guidance</p>	<p>20/04/2026</p>
<p>ribociclib</p> <p>Kisqali®</p> <p>SMC2803</p>	<p>In combination with an aromatase inhibitor for the adjuvant treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer at high risk of recurrence. In pre- or perimenopausal women, or in men, the aromatase inhibitor should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.</p>	<p>Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 17/08/2026</p>	<p>20/04/2026</p>

Medicine	Condition being treated	NHSGGC Decision	Date of decision
sacituzumab Trodelvy® SMC2916	0 Monotherapy for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received endocrine-based therapy, and at least two additional systemic therapies in the advanced setting.	Not routinely available as not recommended for use in NHSScotland	20/04/2026
seladelpar Livdelzi® SMC2899	0 Treatment of primary biliary cholangitis (PBC), including pruritus, in adults in combination with ursodeoxycholic acid (UDCA) who have an inadequate response to UDCA alone, or as monotherapy in those unable to tolerate UDCA.	Not routinely available as not recommended for use in NHSScotland	20/04/2026
Semaglutide Wegovy SMC2497	0 An adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of <ul style="list-style-type: none"> • ≥30kg/m² (obesity), or • ≥27kg/m² to <30kg/m² (overweight) in the presence of at least one weight-related comorbidity. 	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 17/08/2026	20/04/2026
sotatercept Winrevair® SMC2923	0 In combination with other pulmonary arterial hypertension (PAH) therapies, for the treatment of PAH in adult patients with WHO Functional Class (FC) II to III, to improve exercise capacity.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 08/06/2026	20/04/2026

Medicine	Condition being treated	NHSGGC Decision	Date of decision
tirzepatide Mounjaro® SMC2653	For weight management, including weight loss and weight maintenance, as an adjunct to a reduced-calorie diet and increased physical activity in adults with an initial Body Mass Index (BMI) of ≥30 kg/m ² (obesity) or ≥27 kg/m ² to <30 kg/m ² (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus).	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 17/08/2026	20/04/2026
vanzacaftor, tezacaftor, deutivacaftor Alyftrek® SMC2800	Treatment of cystic fibrosis (CF) in people aged 6 years and older who have at least one F508del mutation or another responsive mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 08/06/2026	20/04/2026
vorasidenib Vorango® SMC2844	Treatment of Grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and paediatric patients 12 years and older, who are not in need of immediate chemotherapy or radiotherapy following surgical intervention.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 08/06/2026	20/04/2026
zilucoplan Zilbrysq® SMC2830	As an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.	Not routinely available as not recommended for use in NHSScotland	20/04/2026

Medicine	Condition being treated	NHSGGC Decision	Date of decision
zolbetuximab Vyloy® SMC2839	In combination with fluoropyrimidine- and platinum- containing chemotherapy, for the first-line 0 treatment of adult patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastro-oesophageal junction (GEJ) adenocarcinoma whose tumours are Claudin (CLDN) 18.2 positive.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 17/08/2026	20/04/2026